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INTRODUCTION
Autoimmune thyroiditis (AIT) can be considered as one of
the most frequent organ-specific autoimmune diseases that
affects humans, and its incidence has dramatically increased
over time worldwide (Lerner et al., 2015). AIT raises big
challenge for research as the aetiological factors are still un-
known.
Viral infections have been frequently cited as important en-
vironmental factors implicated in AIT development, al-
though no specific virus has yet been conclusively associ-
ated with the disease. Some evidence implicates human
herpesvirus-6 (HHV-6) in this disease (Chen and Hundall,
2006; Caselli et al., 2012).
HHV-6 is widely distributed in the general population. The
primary infection usually occurs in the early years of life
and remains latent throughout life (Costa et al., 2011).
HHV-6 is associated with several autoimmune diseases,
such as haemolytic anemia (Yagasaki et al., 2011), acute
autoimmune hepatitis (Grima et al., 2008), and multiple
sclerosis (Tejada-Simon et al., 2003). HHV6 has also been
shown to be related to Hashimoto’s thyroiditis. HHV6 was
observed to be more common in thyroid cells in patients
with Hashimoto thyroiditis, than in a control group — 82%
vs 10%, respectively. In addition, there are thyroid cells that
are infected with both HHV-6A and HHV-6B, which have
been shown to be susceptible to natural killer (NK) media-
tors (Caselli et al., 2012). It is possible that HHV-6A/B can
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Viral infections have been frequently cited as important environmental factors implicated in auto-
immune thyroiditis (AIT) development, although no specific virus has yet been conclusively asso-
ciated with the disease. Some evidence implicates human herpesvirus-6 (HHV-6) in this disease.
The aim of this study was to investigate the role of the HHV-6 U83 gene expression in autoim-
mune thyroiditis development. Fifty-one patients with AIT following thyroidectomy and a control
group of 30 autopsied subjects without thyroid pathologies for comparing virology results and 30
healthy blood donors for comparing serology results were enrolled in this study. HHV-6 U83 gene
expression was determined using nested PCR with complementary DNA as the template ac-
quired from thyroid gland extracted RNA. Plasma samples of AIT patients and blood donors were
tested for IL-2, IL-4, IL-10, sTNF-RII and IL-1beta levels by ELISA. Virology results were com-
pared with pro- and anti-inflammatory cytokine levels to determine possible interaction of HHV-6
with host immune response. HHV-6 U83 gene expression was found only in 24% (12/49) of AIT
patient thyroid gland tissue samples and in none of the control group individuals, showing possi-
ble involvement of this gene in AIT development. However, no interaction between HHV-6 and
changes in cytokine levels was found.
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cause autoimmune diseases by exposing a large amount of
normally secreted cell antigens through the infected cell
line. Another potential way of development of the disease
is via molecular mimicry, the synthesis of viral proteins
similar to those of the host cell molecules to avoid the
body's immune response. HHV-6 can cause the major tissue
compatibility of complex molecules to promote the presen-
tation of autoantigens (Broccolo et al., 2013). Like other
herpesviruses, HHV-6 has several biological properties that
could explain the ability of the virus to stimulate and modu-
late the host's immune response, such that the virus is able
to avoid specific immune responses and create better condi-
tions for replication (Wang et al., 2014). For instance, the
regulation of inflammatory cytokines in peripheral blood
mononuclear cells is associated with IL-2 synthesis regula-
tion and subsequent reduction of T-lymphocyte activation.
Such effects are specifically related to HHV-6-encoded pro-
teins that act as analogues to human chemokines and
chemokine receptors and could modulate cytokine produc-
tion influencing the immune response. For example, HHV-6
gene U83 encodes a chemoattractant protein, which is an
agonist for several human chemokine receptors (CCRs), and
the U12 and U51 genes encode chemokine receptors, which
are believed to activate and attract immune cells (Agut et
al., 2015).
The aim of this study was to investigate the role of the
HHV-6 U83 gene expression in autoimmune thyroiditis de-
velopment.
MATERIALS AND METHODS
Study groups. Fifty-one patients with autoimmune thy-
roiditis following thyroidectomy were enrolled in this study,
of which three were males (6%) and 48 were females (94%),
with median age of 52 (interquartile range [IQR]: 41–60).
The control group included 30 autopsied subjects (26
women and four men; median age 58 IQR: 51–67) without
thyroid pathologies, for comparing virology results, and 30
healthy blood donors (25 women and 5 men; median age 33
IQR: 28–45) for comparing serology results, as the plasma
samples from autopsied subjects were not available.
Permission to conduct the study was received from the Rîga
Stradiòð University (RSU) Ethics Committee and all partici-
pants in the study gave their written consent to the examina-
tions. Samples were received from the Rîga Eastern Clinical
University Hospital.
Nucleic acid isolation, complementary DNA (cDNA) syn-
thesis and quality determination. DNA from thyroid
gland tissues was extracted using the phenol-chloroform
method. RNA from thyroid gland tissue and blood speci-
mens was extracted using TRI-reagent (Life Technologies,
USA), and cDNA synthesised using the innuSCRIPT One
Step RT-PCR SyGreen Kit (Analytik Jena, Germany). The
integrity and quality of isolated RNA was tested in denatur-
ing gel electrophoresis using NorthernMax™-Gly Gel
Prep/Running Buffer (Thermo according to manufacturer
protocol (Fisher Scientific, USA). The quality of genomic
DNA obtained from patients and autopsies and synthesised
cDNA was determined by beta ()-globin polymerase chain
reaction (PCR) with the appropriate primers (Vandamme et
al., 1995).
Detection of HHV-6 genomic sequences and gene expres-
sion using nested PCR (nPCR). The nPCR technique was
used to detect viral genomic sequences in DNA isolated
from thyroid gland tissue. PCR amplification of viral DNA
was carried out in the presence of 1 µg of thyroid gland tis-
sue DNA. HHV-6 was detected in accordance with Secchi-
ero et al., 1995. Positive controls (HHV-6A and HHV-6B
genomic DNA; Advanced Biotechnologies Inc, Columbia,
MD, USA and negative controls (DNA obtained from
healthy HHV-6 negative blood donors and without template
DNA) were included in each experiment.
HHV-6 U83 gene expression was detected using nPCR with
cDNA as the template acquired from thyroid gland ex-
tracted RNA with appropriate PCR primers (Sjahril et al.,
2009).
HHV-6 load determination using quantitative PCR. AIT
patient and autopsied subject thyroid tissue DNA samples
that were positive on the presence of HHV-6 genome se-
quence were used for HHV-6 virus load detection using the
HHV-6 Real-TM Quant (Sacace Biotechnologies, Italy)
commercial kit in accordance with the manufacturer's in-
structions.
Determination of IL-2, IL-4, IL-10, sTNF-RII and IL-
1beta levels. Plasma samples acquired from AIT patient
and blood donor peripheral blood were tested for IL-2
(Aviva Systems Biology, USA), IL-4 (Thermo Scientific,
USA), IL-10 (DIAsource, Belgium), sTNF-RII (DIAsource,
Belgium) and IL-1beta (Biorbyt, UK) levels by ELISA
commercial kits. ELISA reagent kits were used and the tests
were carried out in accordance with the manufacturer in-
structions.
Statistical analysis methods. All statistical calculations
and graphs were performed using GraphPad Prism software
version 6.0 for Windows (GraphPad Software, San Diego,
CA, USA). To test whether the collected data were nor-
mally distributed, the D’Agostino and Pearson, Anderson-
Darling and Shapiro-Wilk normality tests were applied. Sta-
tistical differences in the prevalence of HHV-6 infection
were assessed using the Fisher exact test. Statistical differ-
ences in viral load and serological results were assessed us-
ing the Mann–Whitney test. Because most of the data did
not have a normal distributions, results are expressed as me-
dian and interquartile range (IQR) as a variability character-
istic, and a p-value of less than 0.05 (p < 0.05) was consid-
ered as statistically significant.
RESULTS
The presence of persistent HHV-6 infection in AIT patients
was significantly higher (p = 0.0111) than in the control
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group (96% and 77%, respectively). The HHV-6 genomic
sequence was found in 49 of thyroid tissue DNA samples of
the 51 (96%) patients. In contrast, the HHV-6 genome se-
quence was found in 23 of the 30 (77%) DNA samples iso-
lated from autopsy material of the control group (Fig. 1).
No HHV-6 U83 gene expression was observed in thyroid
gland tissue samples from the control group. In contrast,
HHV-6 U83 mRNA was identified in thyroid tissue samples
of 12 of 49 (25%) AIT patients, which wasa significantly
higher than in the control group (p = 0071) (Fig. 1).
The HHV-6 load was determined for the patient and control
group thyroid gland tissue samples positive after nPCR.
Median HHV-6 load was found higher in AIT patient thy-
roid gland tissue samples (582.7 IQR: 168.4–2191.0) in
comparison to that in the control group (361.0 IQR:
110.0–1029.0); however, the Mann-Whitney test showed no
significance (p = 0.2209) (Fig. 2).
Comparison of results on HHV-6 load found in patient thy-
roid gland samples positive for the presence and absence of
HHV-6 U83 mRNA showed a higher median value in the
former (913.0 IQR: 248.0–2049.0 vs 486.8 IQR:
168.4–2191.0), but without statistical significance (Mann–
Whitney test, p = 0.4820) (Fig. 3).
To examine possible immunomodulating interactions of
HHV-6 U83 gene all patient peripheral blood plasma sam-
ples were tested for IL-1, IL-2, IL-4, IL-10 and sTNF-RII
using ELISA commercial kits. To determine overall differ-
ences in cytokine levels between AIT patients and healthy
individuals, cytokine levels were also measured in plasma
samples acquired from the blood donors.
The IL-1 level in all AIT patient and blood donor plasma
samples was < 1 pg/ml. No difference in IL-2 levels was
found between the patient and control groups (median 1.503
U/ml IQR: 1.379–1.689 against 1.503 U/ml IQR: 1.410–
1.907, respectively). Likewise, there was no significant dif-
ference in sTNF-RII levels between patient and control
groups (median 6.037 ng/ml IQR: 4.402–8.234 against
5.523 ng/ml IQR: 4.213–7.206, respectively). In contrast, a
significant difference (p = 0.0033) was found in the IL-4
levels. The median amount of IL-4 was lower in AIT patient
plasma samples in comparison to that of control groups
(10.62 pg/ml IQR: 8.31–12.15 vs 12.15 pg/ml IQR:
10.62–17.15, respectively). Also, the level of IL-10 was sig-
nificantly (p = 0.0022) higher in AIT patient plasma sam-
ples than in the control groups (median 52.00 pg/ml IQR:
37.00–104.50 against 24.50 pg/ml IQR: 12.00–114.50, re-
spectively) (Fig. 4).
A closer analysis of cytokine levels in the patient group
showed no significance difference between cytokine levels
in HHV-6 U83 mRNA positive and negative samples. The
corresponding medians for cytokine levels in the AIT pa-
tients with and without HHV-6 U83 mRNA were: IL-2
1.472 (IQR: 1.332–1.658) U/ml against 1.503 (IQR:
1.441–1.752) U/ml, IL-4 10.62 (IQR: 7.923–15.04) pg/ml
against 11.38 (IQR: 9.269–13.69) pg/ml, IL-10 50.75 (IQR:
38.25–94.5) pg/ml against 54.5 (IQR: 37–104.5) pg/ml,
sTNF-RII 6.037 (IQR: 3.981–7.953) ng/ml against 6.084
(IQR: 4.402–8.234) ng/ml, respectively (Fig. 5).
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Fig. 1. Presence of HHV-6 genomic sequence and HHV-6 U83 mRNA in
thyroid gland tissues acquired from AIT patients and autopsied individuals
(control group).
Fig. 2. Comparison of HHV-6 load between AIT patient and control thy-
roid gland samples. Statistical differences in viral load comparison were
tested using the Mann–Whitney test. As most of the data lacked norla dis-
tribution, results are expressed as median and interquartile range (IQR) as a
variability characteristic, and p < 0.05 was considered as statistically sig-
nificant. Each point represents one individual.
Fig. 3. Comparison of HHV-6 load in samples of the patient thyroid gland
with presence and absence of HHV-6 U83 gene expression. Statistical dif-
ferences in viral load comparison were tested using the Mann–Whitney
test. As most of the data lack normal distributions, the results are expressed
as median and interquartile range (IQR) as a variability characteristic, and
p < 0.05 was considered as statistically significant. Each point represents
an individual.
Fig. 4. Levels of IL-2, IL-4, IL-10 and sTNF-RII with median and IQR in AIT patient and donor plasma. Statistical differences were assessed using the
Mann–Whitney test and p < 0.05 was considered as statistically significant. Each point represents an individual.
Fig. 5. Levels of IL-2, IL-4, IL-10 and sTNF-RII in AIT patients' peripheral blood plasma (median with IQR) with and without HHV-6 U83 mRNA in thy-
roid gland. In acquirement of statistical differences was used Mann–Whitney test and p < 0.05 was considered as statistically significant. Each point repre-
sents each individual's result.
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DISCUSSION
While autoimmune thyroiditis is one of the most frequent
autoimmune diseases, its precise prevalence in Latvia is un-
known. Moreover, diagnosis and treatment of AIT in Latvia
is associated with many issues and one of them is related to
the lack of differential diagnosis. Early differential diagno-
sis could allow to apply required treatment and to avoid
progression of diseases with subsequent surgical interfer-
ence (thyroidectomy). Identification of potential pathogens
and interaction mechanisms could help in diagnosing of
autoimmune disease in the early stages of development as
well as in choosing appropriate treatments to avoid the re-
moval of the thyroid gland when unnecessary.
Viral infections have been considered as possible disease-
promoting factors in various studies (Caselli et al., 2012).
Our recent study showed a very high frequency rate (99%)
of the HHV-6B genomic sequence in AIT patient thyroid
gland tissues and 41% of tissues contained markers of ac-
tive HHV-6 infection (presence of HHV-6 U79/80 mRNA)
(Sultanova et al., 2017). These results corroborate the re-
sults of this study, where 96% of thyroid gland tissue sam-
ples were HHV-6 positive. This could serve as evidence for
thyroid gland tissues as persistence site of HHV-6 and indi-
cate the possible involvement of HHV-6 in AIT develop-
ment. This supports other studies, but the exact mechanism
of possible interactions of HHV-6 in AIT development is
not yet clear.
Some studies have reported that specific viruses are in-
volved in molecular piracy and mimicry mechanisms, in
this way acquiring host genes within virus genomes, which
makes them able to produce proteins capable of interfering
with the normal host defence response (Wells and Schwartz,
1997). HHV-6 is an immunomodulating virus and encodes
one viral chemokine (U83) and two chemokine receptors
(U12 and U51); however, the role of these genes in viral
pathogenesis is not well understood (Isegawa et al., 1998;
Zou et al., 1999; Menotti et al., 1999). One study has shown
that HHV-6 viral chemokine U83 has the ability to promote
the migration of monocytes/macrophages (Zou et al., 1999).
Therefore, this viral chemokine might be involved in induc-
tion of autoimmune processes. The aim of this study was to
investigate the possible interaction between HHV-6 U83
gene expression and some pro-inflammatory and anti-in-
flammatory cytokines.
HHV-6 U83 gene expression was found only in 24%
(12/49) of AIT patients' thyroid gland tissue samples and in
none of the control group individuals, showing possible in-
volvement of this gene in AIT development. However,
there was no significant difference in IL-4 and IL-10 levels
between the AIT patient and control group. Within the pa-
tients' group there was no association between cytokine
level and presence and absence of HHV-6 U83 gene ex-
pression in thyroid gland. As the HHV-6 U83 gene encodes
a putative chemokine that could modulate immune re-
sponses, our main hypothesis was to test for differences in
cytokine level. However, the results showed lack of effect
of this gene on cytokine levels, which can have several ex-
planations. Firstly, only a small part of the group was
positive for HHV-6 U83 gene expression, indicating that the
studied group was too small. Another issue was the use of
ELISA kits from the different manufactures with different
sensitivities, which could have been resolved by using a
more sensitive method like suspension multiplex immuno-
assay for Luminex 200 system application. This method al-
lows simultaneous measuring and detecting more than one
cytokine in a sample.
The observed significant difference between patient and
control groups in IL-4, and IL-10 levels showed a shift in
humoral immune response as these both cytokines are stim-
ulating B lymphocyte antibody production (Hershey et al.,
1997; Aster et al., 2009). The presence of IL-4 might pro-
mote alternative activation of macrophages into M2 cells
and inhibit classical activation of macrophages into M1
cells. An increase in repair of macrophages (M2) is coupled
with secretion of IL-10 and TGF-, which results in a dimi-
nution of pathological inflammation (Aster et al., 2009).
This mechanism should be studied much closer in conjunc-
tion with HHV-6 interference, as it might provide new evi-
dence of involvement of this virus in AIT development.
Nevertheless, due to complex ethiopathogenesis of AIT,
other various factors that might cause immunomodulation
could not be excluded.
Another way to expand this study is to add HHV-6 U12 and
U51 encoded chemokine receptors similar to G protein cou-
pled receptor (GPCR) in the study. It has been shown that
proteins encoded by HHV-6 U12 and U51 genes can be ex-
pressed on the surface of epithelial and some peripheral
blood mononuclear cell populations, which might make
them the potential cause for evoking autoimmunity and
make host GPCRs as targets for auto-reactive T and B lym-
phocytes (Isegawa et al., 1998; Menotti et al., 1999; Milne
et al., 2000). Also, it has been shown in vitro that HHV-6
specific GPCRs can interact with cytokine signalling path-
ways by down-regulating RANTES (Milne et al., 2000). On
the basis of this knowledge, both U12 and U51 proteins are
ideal objects for study of HHV-6 involvement in autoim-
mune thyroiditis development, in contrast to the approach in
the present study.
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CILVÇKA HERPESVÎRUSA-6 U83 GÇNA EKSPRESIJAS IESPÇJAMÂ LOMA AUTOIMÛNÂ TIREOIDÎTA ATTÎSTÎBÂ
Vîrusu infekcija bieþi tiek minçta kâ nozîmîgs faktors autoimûnâ tireodîta (AIT) attîstîbâ. Lai gan lîdz ðim konkrçtais vîruss nav pârliecinoði
sasaistîts ar AIT, ir pierâdîjumi, ka cilvçka herpesvîrusam-6 ir nozîme slimîbas attîstîbâ. Pçtîjuma mçríis bija izpçtît HHV-6 gçna U83
ekspresijas iespçjamo lomu autoimûnâ tireoidîta attîstîbâ. Pçtîjumâ tika iekïauts 51 pacients ar autoimûno tireoidîtu pçc tireoîdektomijas, 30
autopsijas paraugi bez vairogdziedzera patoloìijâm virusoloìisko rezultâtu salîdzinâðanai un 30 veseli asins donori seroloìijas rezultâtu
salîdzinâðanai. HHV-6 U83 gçna ekspresija tika noteikta ar polimerâzes íçdes reakciju ar iekðçjo praimçðanu, kâ matricu lietojot
komplementâru DNS, kas ar attiecîgiem praimeriem sintezçta no vairogdziedzera audiem izdalîtâs RNS. Lietojot ELISA, AIT pacientu un
asins donoru plazmâ tika noteikts IL-2, IL-4, IL-10, sTNF-RII un IL-1beta lîmenis. Lai novçrtçtu iespçjamo mijiedarbîbu starp HHV-6 un
organisma imûnsistçmas atbildi, virusoloìiskie rezultâti tika salîdzinâti ar iekaisuma un pretiekaisuma citokînu lîmeòiem. HHV6 gçnu
ekspresija tika detektçta 24% (12/49) no AIT pacientu vairogdziedzera audu paraugos un nevienâ no kontroles grupas indivîdu paraugiem,
kas norâda uz ðî gçna iespçjamu iesaisti AIT attîstîbâ. Taèu saistîba starp HHV-6 U83 ekspresiju un citokînu lîmeòu izmaiòâm netika
atrasta.
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